دورية أكاديمية

Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.

التفاصيل البيبلوغرافية
العنوان: Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.
المؤلفون: Zarogoulidis, Paul, Chinelis, Panos, Athanasiadou, Anastasia, Tsiouda, Theodora, Trakada, Georgia, Kallianos, Anastasios, Veletza, Lemonia, Hatzibougias, Dimitris, Mihalopoulou, Electra, Goupou, Eirini, Kosmidis, Christoforos, Sardeli, Chrysanthi, Huang, Haidong, Hohenforst-Schmidt, Wolfgang
المصدر: Respiratory Medicine Case Reports; 2017, Vol. 22, p101-105, 5p
مستخلص: In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients. [ABSTRACT FROM AUTHOR]
Copyright of Respiratory Medicine Case Reports is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Supplemental Index
الوصف
تدمد:22130071
DOI:10.1016/j.rmcr.2017.07.004